- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphoblastic leukemia、childhood acute lymphoblastic leukemia、childhood ALL、L1 acute lymphocytic leukemia、L2 acute lymphoblastic leukemia、L2 acute lymphocytic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma
WordNet
- small room in which a monk or nun lives (同)cubicle
- a device that delivers an electric current as the result of a chemical reaction (同)electric cell
- a room where a prisoner is kept (同)jail cell, prison cell
- (biology) the basic structural and functional unit of all organisms; they may exist as independent units of life (as in monads) or may form colonies or tissues as in higher plants and animals
- any small compartment; "the cells of a honeycomb"
- a small unit serving as part of or as the nucleus of a larger political movement (同)cadre
- a substance from which another substance is formed (especially by a metabolic reaction)
- a person who goes before or announces the coming of another (同)forerunner
- malignant neoplasm of blood-forming tissues; characterized by abnormal proliferation of leukocytes; one of the four major types of cancer (同)leukaemia, leucaemia, cancer of the blood
- a neoplasm of lymph tissue that is usually malignant; one of the four major types of cancer
- an immature lymphocyte
PrepTutorEJDIC
- (刑務所の)『独房』;(修道院の)小さい独居室 / (ミツバチの)みつ房,巣穴 / 小さい部屋 / 『細胞』 / 電池 / 花粉室 / (共産党などの)細胞
- (…の)前朕,前触れ《+『of』+『名』》
- 白血病
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 前駆B細胞性急性リンパ芽球性白血病／リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of precursor b cell acute lymphoblastic leukemia lymphoma
- 2. 前駆T細胞性急性リンパ芽球性白血病／リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of precursor t cell acute lymphoblastic leukemia lymphoma
- 3. 造血腫瘍の分類 classification of the hematopoietic neoplasms
- 4. 小児における急性リンパ芽球性白血病のリスクグループ層別化および予後 risk group stratification and prognosis for acute lymphoblastic leukemia in children
- 5. 非ホジキンリンパ腫の病理の概要 overview of the pathobiology of the non hodgkin lymphomas
English Journal
- Targeting STAT5 in Hematological Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2.
- Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DA.Author information 1Harvard University, Dana Farber Cancer Institute.AbstractThe transcription factor signal transducer and activator of transcription 5 (STAT5) is constitutively activated in a wide range of leukemias and lymphomas, and drives the expression of genes necessary for proliferation, survival, and self-renewal. Thus, targeting STAT5 is an appealing therapeutic strategy for hematological malignancies. Given the importance of bromodomain-containing proteins in transcriptional regulation, we considered the hypothesis that a pharmacological bromodomain inhibitor could inhibit STAT5-dependent gene expression. We found that the small molecule bromodomain and extra-terminal (BET) bromodomain inhibitor JQ1 decreases STAT5-dependent (but not STAT3-dependent) transcription of both heterologous reporter genes and endogenous STAT5 target genes. JQ1 reduces STAT5 function in leukemia and lymphoma cells with constitutive STAT5 activation, or inducibly activated by cytokine stimulation. Among the BET bromodomain sub-family of proteins, it appears that BRD2 is the critical mediator for STAT5 activity. In experimental models of acute T cell lymphoblastic leukemias, where activated STAT5 contributes to leukemia cell survival, Brd2 knock-down or JQ1 treatment shows strong synergy with tyrosine kinase inhibitors in inducing leukemia cells apoptosis. By contrast, mononuclear cells isolated form umbilical cord blood, which is enriched in normal hematopoietic precursor cells, were unaffected by these combinations. These findings indicate a unique functional association between BRD2 and STAT5, and suggest that combinations of JQ1 and tyrosine kinase inhibitors may be an important rational strategy for treating leukemias and lymphomas driven by constitutive STAT5 activation.
- Molecular cancer therapeutics.Mol Cancer Ther.2014 Jan 16. [Epub ahead of print]
- The transcription factor signal transducer and activator of transcription 5 (STAT5) is constitutively activated in a wide range of leukemias and lymphomas, and drives the expression of genes necessary for proliferation, survival, and self-renewal. Thus, targeting STAT5 is an appealing therapeutic st
- PMID 24435449
- High proportions of CD4⁺ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses.
- Lustfeld I, Altvater B, Ahlmann M, Ligges S, Brinkrolf P, Rosemann A, Moericke A, Rossig C.Author information Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.AbstractResidual nonmalignant T cells in the bone marrow of patients with acute leukemias may be involved in active immune responses to leukemic cells. Here, we investigated the phenotypic signature of T cells present at diagnosis in 39 pediatric patients with acute lymphoblastic leukemia (ALL) treated within standardized ALL-BFM study protocols. Previously described age associations of lymphocyte subpopulations in the peripheral blood of healthy children were reproduced in leukemic bone marrow. Analysis of individual lymphocyte parameters and risk-associated variables using univariate linear regression models revealed a correlation of higher CD4/CD8 ratios at diagnosis with a favorable bone marrow response on day 15. Separate analysis of CD4⁺ cells with the CD4⁺CD25(hi)FoxP3⁺ T(reg) cell phenotype showed that the association was caused by non-T(reg) CD4⁺ cells. The association of higher CD4/CD8 ratios with a favorable bone marrow response on day 15 of treatment persisted in a cohort extended to 69 patients. We conclude that CD4⁺ non-T(reg) cells in leukemic bone marrow at diagnosis may have a role in early response to treatment. Prospective analysis of the CD4/CD8 ratio in a large cohort of pediatric patients is now needed. Moreover, future experiments will establish the functional role of the individual T cell subsets in immune control in pediatric ALL.
- Acta haematologica.Acta Haematol.2014;131(1):28-36. doi: 10.1159/000351429. Epub 2013 Sep 10.
- Residual nonmalignant T cells in the bone marrow of patients with acute leukemias may be involved in active immune responses to leukemic cells. Here, we investigated the phenotypic signature of T cells present at diagnosis in 39 pediatric patients with acute lymphoblastic leukemia (ALL) treated with
- PMID 24021585
- New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
- Hales EC, Taub JW, Matherly LH.Author information Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, United States.AbstractT-cell acute lymphoblastic leukemia (T-ALL) is characterized as a high-risk stratified disease associated with frequent relapse, chemotherapy resistance, and a poorer prognostic outlook than B-precursor ALL. Many of the challenges in treating T-ALL reflect the lack of prognostic cytogenetic or molecular abnormalities on which to base therapy, including targeted therapy. Notch1 activating mutations were identified in more than 50% of T-ALL cases and can be therapeutically targeted with γ-secretase inhibitors (GSIs). Mutant Notch1 can activate cMyc and PI3K-AKT-mTOR1 signaling in T-ALL. In T-ALLs with wild-type phosphatase and tensin homolog deleted on chromosome ten (PTEN), Notch1 transcriptionally represses PTEN, an effect reversible by GSIs. Notch1 also promotes growth factor receptor (IGF1R and IL7Rα) signaling to PI3K-AKT. Loss of PTEN is common in primary T-ALLs due to mutation or posttranslational inactivation and results in chronic activation of PI3K-AKT-mTOR1 signaling, GSI-resistance, and repression of p53-mediated apoptosis. Notch1 itself might regulate posttranslational inactivation of PTEN. PP2A is activated by Notch1 in PTEN-null T-ALL cells, and GSIs reduce PP2A activity and increase phosphorylation of AKT, AMPK, and p70S6K. This review focuses on the central role of the PI3K-AKT-mTOR1 signaling in T-ALL, including its regulation by Notch1 and potential therapeutic interventions, with emphasis on GSI-resistant T-ALL.
- Cellular signalling.Cell Signal.2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16.
- T-cell acute lymphoblastic leukemia (T-ALL) is characterized as a high-risk stratified disease associated with frequent relapse, chemotherapy resistance, and a poorer prognostic outlook than B-precursor ALL. Many of the challenges in treating T-ALL reflect the lack of prognostic cytogenetic or molec
- PMID 24140475
- Assessment of gross motor skills and phenotype profile in children 9-11 years of age in survivors of acute lymphoblastic leukemia.
- Leone M, Viret P, Bui HT, Laverdière C, Kalinova É, Comtois AS.Author information Kinesiology Department of Health Sciences, Kinesiology Division and Health Sciences Department, University of Québec in Chicoutimi, Saguenay, Québec, Canada; Centre de Recherche Interdisciplinaire sur la Qualité et les Saines Habitudes de vie, University of Québec in Chicoutimi, Saguenay, Québec, Canada.AbstractBACKGROUND: The purpose of this study was to evaluate the usefulness of a new gross motor skill test battery in acute lymphoblastic leukemia (ALL) children who have been off therapy for at least 1 year and to assess its discriminatory power (discriminant analysis) from healthy children.
- Pediatric blood & cancer.Pediatr Blood Cancer.2014 Jan;61(1):46-52. doi: 10.1002/pbc.24731. Epub 2013 Sep 21.
- BACKGROUND: The purpose of this study was to evaluate the usefulness of a new gross motor skill test battery in acute lymphoblastic leukemia (ALL) children who have been off therapy for at least 1 year and to assess its discriminatory power (discriminant analysis) from healthy children.PROCEDURE: Tw
- PMID 24115507
Japanese Journal
- 両側腎多発結節状腫瘤と多発脊椎転移病変を認めた前駆B細胞性リンパ芽球性リンパ腫の1例
- 日本小児血液・がん学会雑誌 53(2), 135-138, 2016
- NAID 130005161919
- 縦隔悪性リンパ腫 (特集 縦隔腫瘍の画像診断をめぐって)
- 日本胸部臨床 69(11), 1019-1030, 2010-11
- NAID 40017370695
- Ｂ前駆細胞型急性リンパ性白血病の治療
- 日本小児血液学会雑誌 22(4), 259-266, 2008
- NAID 130004345997
- Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma
- Pathology international 57(2), 53-59, 2007-02-01
- NAID 10020104959
Related Links
- 1: Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in ...
- Read more about the pharmacogenomics of Precursor Cell Lymphoblastic Leukemia-Lymphoma on PharmGKB. ... Alternate Names: Synonym ALL, Childhood; Acute Lymphoblastic Leukemia; Acute Lymphoblastic ...
- In the WHO classification system for hematologic malignancies, the lymphoblastic neoplasms, which may present as leukemia and/or lymphoma, are divided into two general categories based upon lineage (see):Precursor B cell ...
Related Pictures
★リンクテーブル★
「adult acute lymphoblastic leukemia」
- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphocytic leukemia、childhood acute lymphoblastic leukemia、childhood ALL、L1 acute lymphocytic leukemia、L2 acute lymphoblastic leukemia、L2 acute lymphocytic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma、precursor cell lymphoblastic leukemia-lymphoma
「childhood ALL」
- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphoblastic leukemia、childhood acute lymphoblastic leukemia、L1 acute lymphocytic leukemia、L2 acute lymphoblastic leukemia、L2 acute lymphocytic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma、precursor cell lymphoblastic leukemia-lymphoma
「L1 acute lymphocytic leukemia」
- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphoblastic leukemia、childhood acute lymphoblastic leukemia、childhood ALL、L2 acute lymphoblastic leukemia、L2 acute lymphocytic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma、precursor cell lymphoblastic leukemia-lymphoma
「L2 acute lymphocytic leukemia」
- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphoblastic leukemia、childhood acute lymphoblastic leukemia、childhood ALL、L1 acute lymphocytic leukemia、L2 acute lymphoblastic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma、precursor cell lymphoblastic leukemia-lymphoma
「L2 acute lymphoblastic leukemia」
- 関
- acute lymphoblastic leukemia、acute lymphocytic leukemia、acute lymphoid leukemia、adult acute lymphoblastic leukemia、childhood acute lymphoblastic leukemia、childhood ALL、L1 acute lymphocytic leukemia、L2 acute lymphocytic leukemia、lymphoblastic leukemia、lymphoblastic lymphoma、precursor cell lymphoblastic leukemia-lymphoma
「precursor」
- n.
「lymphoblastic」
- adj.
- リンパ芽球性の、リンパ芽球の
「lymphoblast」